DrugPatentWatch Database Preview

Drugs in Development Information for Anlotinib

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Anlotinib?

Anlotinib is an investigational drug.

There have been 207 clinical trials for Anlotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30^th 2018.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, and Sun Yat-sen University.

There are ten US patents protecting this investigational drug and seventy-two international patents.

Summary for Anlotinib

US Patents	10
International Patents	72
US Patent Applications	29
WIPO Patent Applications	34
Japanese Patent Applications	7
Clinical Trial Progress	Phase 2 (2018-11-30)
Vendors	20

Recent Clinical Trials for Anlotinib

Title	Sponsor	Phase
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC	Allist Pharmaceuticals, Inc.	Phase 2

See all Anlotinib clinical trials

Clinical Trial Summary for Anlotinib

Top disease conditions for Anlotinib

Top clinical trial sponsors for Anlotinib

See all Anlotinib clinical trials

US Patents for Anlotinib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Anlotinib		Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts	Advenchen Pharmaceuticals, LLC (Moorpark, CA)
Anlotinib		Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
Anlotinib		Method for treating tumour, pharmaceutical composition and medicinal kit
Anlotinib		Quinoline derivative against non-small cell lung cancer
Anlotinib		Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts	Advenchen Pharmaceuticals, LLC (Moorpark, CA)
Anlotinib		Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof	Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Lianyungang, CN)

International Patents for Anlotinib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Anlotinib	Australia	AU2016257816	2035-05-04
Anlotinib	Brazil	BR112017023639	2035-05-04
Anlotinib	Canada	CA2984444	2035-05-04
Anlotinib	China	CN107771078	2035-05-04
Anlotinib	China	CN110172057	2035-05-04
Anlotinib	China	CN110292579	2035-05-04